(Total Views: 440)
Posted On: 08/13/2024 2:38:55 PM
Post# of 151605
Quote:
The phase 3 trial of Trifluridine/Tipiracil with Bevacizumab was not restricted to MSS mCRC. Although most patients are MSS, will this confound the comparison to our trial results?
Being fourth line there is a short timeline to death so there should be little difference between refractory or MSS CRC.
(6)
(0)Scroll down for more posts ▼
